tbuckley/cabot-search huggingface dataset:
Arsenic Trioxide (AS2O3) Therapy for Relapsed Acute Promyelocytic Leukemia (APL): Comparison with a Historic Control Combining All-Trans Retinoic Acid (ATRA) Plus Intensive Chemotherapy.
Authors: Xavier Thomas, Arnaud Pigneux, Emmanuel Raffoux, Francoise Huguet, Denis Caillot, Agnes Guerci, Aspasia Stamatoullas, Oumedaly Reman, Francoise Isnard, Francois Dreyfus, Nicole Gratecos, Marc Bernard, Yazid Arkam, Pierre Fenaux
Journal: Blood (2005)
Methylation Patterns in Waldenströms Macroglobulinemia Cells That Are Inherently Resistant or Have Acquired Resistance to Bortezomib, Converge on the TP63 and Cepba Family of Transcription Factors
Authors: Aneel Paulus, Xue Wang, Sharoon Akhtar, Maja Kuranz-Blake, Anne Novak, Stephen M Ansell, Morie A Gertz, Robert A Kyle, Peter Martin, Morton Coleman, Sikander Ailawadhi, Asher Chanan-Khan, Kasyapa S. Chitta
Journal: Blood (2014)
Testosterone and Male Aging
Authors: David J. Handelsman
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Nepafenac 0.3% after Cataract Surgery in Patients with Diabetic Retinopathy
Authors: Rishi P. Singh, Robert Lehmann, Joseph Martel, Kevin Jong, Ayala Pollack, Alexis Tsorbatzoglou, Giovanni Staurenghi, Guadalupe Cervantes-Coste Cervantes, Louis Alpern, Satish Modi, Liza Svoboda, Adeniyi Adewale, Glenn J. Jaffe
Journal: Ophthalmology (2017)

To demonstrate the efficacy and safety of once-daily nepafenac 0.3% ophthalmic suspension versus vehicle, based on clinical outcomes, after cataract surgery in patients with diabetes.Two prospective, randomized, multicenter, double-masked, vehicle-controlled phase 3 studies.Total, 615 patients in study 1 and 605 patients in study 2.Patients were randomized (1:1) to topical nepafenac 0.3% or vehicle once-daily starting the day before surgery and continuing for 90 days thereafter.Key efficacy variables were: patients (%) in whom macular edema (ME) developed (≥30% increase from preoperative baseline central subfield macular thickness) within 90 days after cataract surgery and the patients (%) with a best-corrected visual acuity (BCVA) improvement of ≥15 letters from preoperative baseline through day 14 maintained through day 90. Secondary end points included: patients (%) with a BCVA improvement of ≥15 letters from preoperative baseline through days 90 and 60 and safety over 3 months.A significantly lower percentage of patients demonstrated ME within 90 days after surgery with nepafenac 0.3% versus vehicle (study 1: 2.3% vs. 17.3%; P < 0.001; study 2: 5.9% vs. 14.3%; P = 0.001; pooled: 4.1% vs. 15.9%; P < 0.001). The percentage of patients achieving a ≥15-letter improvement from baseline through day 14 maintained through day 90 with nepafenac 0.3% versus vehicle was 61.7% versus 43.0% (P < 0.001) in study 1, 48.8% versus 50.5% (P = 0.671) in study 2, and 55.4% versus 46.7% (P = 0.003) in the pooled analysis. A greater percentage of patients treated with nepafenac 0.3% versus vehicle in study 1 and similar percentage in study 2 had a BCVA improvement of ≥15 letters from preoperative baseline through day 90 (77.2% vs. 67.7% [P = 0.009] and 65.4% vs. 65.9% [P = 0.888]) and through day 60 (76.2% vs. 64.7% [P = 0.002] and 68.9% vs. 62.1% [P = 0.092]). No unanticipated adverse events were observed.These studies demonstrated the clinical benefits of nepafenac 0.3% over vehicle in reducing the risk of postoperative ME, with the integrated analysis showing improved BCVA after cataract surgery in patients with diabetic retinopathy, with no unanticipated safety events.
Post-transcriptional regulation of fruit ripening and disease resistance in tomato by the vacuolar protease SlVPE3
Authors: Weihao Wang, Jianghua Cai, Peiwen Wang, Shiping Tian, Guozheng Qin
Journal: Genome biology (2017)

Proteases represent one of the most abundant classes of enzymes in eukaryotes and are known to play key roles in many biological processes in plants. However, little is known about their functions in fruit ripening and disease resistance, which are unique to flowering plants and required for seed maturation and dispersal. Elucidating the genetic mechanisms of fruit ripening and disease resistance is an important goal given the biological and dietary significance of fruit. Through expression profile analyses of genes encoding tomato (Solanum lycopersicum) cysteine proteases, we identify a number of genes whose expression increases during fruit ripening. RNA interference (RNAi)-mediated repression of SlVPE3, a vacuolar protease gene, results in alterations in fruit pigmentation, lycopene biosynthesis, and ethylene production, suggesting that SlVPE3 is necessary for normal fruit ripening. Surprisingly, the SlVPE3 RNAi fruit are more susceptible to the necrotrophic pathogen Botrytis cinerea. Quantitative proteomic analysis identified 314 proteins that differentially accumulate upon SlVPE3 silencing, including proteins associated with fruit ripening and disease resistance. To identify the direct SlVPE3 targets and mechanisms contributing to fungal pathogen resistance, we perform a screening of SlVPE3-interacting proteins using co-immunoprecipitation coupled with mass spectrometry. We show that SlVPE3 is required for the cleavage of the serine protease inhibitor KTI4, which contributes to resistance against the fungal pathogen B. cinerea. Our findings contribute to elucidating gene regulatory networks and mechanisms that control fruit ripening and disease resistance responses.
Inflammatory monocytes require type I interferon receptor signaling to activate NK cells via IL-18 during a mucosal viral infection
Authors: Amanda J. Lee, Branson Chen, Marianne V. Chew, Nicole G. Barra, Mira M. Shenouda, Tina Nham, Nico van Rooijen, Manel Jordana, Karen L. Mossman, Robert D. Schreiber, Matthias Mack, Ali A. Ashkar
Journal: The Journal of Experimental Medicine (2017)

The requirement of type I interferon (IFN) for natural killer (NK) cell activation in response to viral infection is known, but the underlying mechanism remains unclear. Here, we demonstrate that type I IFN signaling in inflammatory monocytes, but not in dendritic cells (DCs) or NK cells, is essential for NK cell function in response to a mucosal herpes simplex virus type 2 (HSV-2) infection. Mice deficient in type I IFN signaling, Ifnar −/− and Irf9 −/− mice, had significantly lower levels of inflammatory monocytes, were deficient in IL-18 production, and lacked NK cell–derived IFN-γ. Depletion of inflammatory monocytes, but not DCs or other myeloid cells, resulted in lower levels of IL-18 and a complete abrogation of NK cell function in HSV-2 infection. Moreover, this resulted in higher susceptibility to HSV-2 infection. Although Il18 −/− mice had normal levels of inflammatory monocytes, their NK cells were unresponsive to HSV-2 challenge. This study highlights the importance of type I IFN signaling in inflammatory monocytes and the induction of the early innate antiviral response.
Risk-Adapted Therapy of Aggressive Lymphoma Based on FDG-PET Performed after 2 or 3 Cycles of Initial Chemotherapy.
Authors: Yvette L. Kasamon, Richard L. Wahl, Harvey A. Ziessman, Caroline Fidyk, Kathryn Rogers, Genea Smith, Richard J. Jones, Richard F. Ambinder, Lode J. Swinnen
Journal: Blood (2007)
NUP98-HOXA9 Reprograms Embryonic Hematopoiesis, Suppresses Cellular Apoptosis, and Causes Malignant Tissue Infiltrates in Transgenic Zebrafish.
Authors: A. Michael Forrester, Ellen R. Boyd, Clemens Grabher, Eileen R. McBride, Sahar Da'as, Fui Boon Kai, A. Thomas Look, Jason N. Berman
Journal: Blood (2009)
Bone Marrow-Derived Mensenchymal Stem Cells Modified by Mouse Interferon-γ Gene Reduce Fibrosis and Improve Function In a Mouse Model of Liver Fibrosis.
Authors: Hongli Xue, Shijia Ling, Dong He, Yanjun Wen, Wentong Meng, Ting Niu
Journal: Blood (2010)
Epidermal Inorganic Optoelectronics for Blood Oxygen Measurement
Authors: Haicheng Li, Yun Xu, Xiaomin Li, Ying Chen, Yu Jiang, Changxing Zhang, Bingwei Lu, Jian Wang, Yinji Ma, Yihao Chen, Yin Huang, Minquang Ding, Honghong Su, Guofeng Song, Yi Luo, X. Feng
Journal: Advanced Healthcare Materials (2017)

Flexible and stretchable optoelectronics, built-in inorganic semiconductor materials, offer a wide range of unprecedented opportunities and will redefine the conventional rigid optoelectronics in biological application and medical measurement. However, a significant bottleneck lies in the brittleness nature of rigid semiconductor materials and the performance's extreme sensitivity to the light intensity variation due to human skin deformation while measuring physical parameters. In this study, the authors demonstrate a systematic strategy to design an epidermal inorganic optoelectronic device by using specific strain-isolation design, nanodiamond thinning, and hybrid transfer printing. The authors propose all-in-one suspension structure to achieve the stretchability and conformability for surrounding environment, and they propose a two-step transfer printing method for hybrid integrating III-V group emitting elements, Si-based photodetector, and interconnects. Owing to the excellent flexibility and stretchability, such device is totally conformal to skin and keeps the constant light transmission between emitting element and photodetector as well as the signal stability due to skin deformation. This method opens a route for traditional inorganic optoelectronics to achieve flexibility and stretchability and improve the performance of optoelectronics for biomedical application.
Increasing Frequency of T Cell Immunosuppressive Receptor Expression in CD4+ and CD8+ T Cells May Related to T Cell Exhaustion and Immunosuppression in Patients with AML
Authors: Jiaxiong Tan, Shaohua Chen, Ling Xu, Shuai Lu, Yikai Zhang, Jie Chen, Lijian Yang, Jing Lai, Yuhong Lu, Zhi Yu, Yangqiu Li
Journal: Blood (2016)
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
Authors: Reinhard Dummer, Dirk Schadendorf, Paolo A Ascierto, Ana Arance, Caroline Dutriaux, Anna Maria Di Giacomo, Piotr Rutkowski, Michele Del Vecchio, Ralf Gutzmer, Mario Mandala, Luc Thomas, Lev Demidov, Claus Garbe, David Hogg, Gabriella Liszkay, Paola Queirolo, Ernesto Wasserman, James Ford, Marine Weill, L Andres Sirulnik, Valentine Jehl, Viviana Bozón, Georgina V Long, Keith Flaherty
Journal: The Lancet Oncology (2017)
C-KIT- Mutated t(8;21)AML Patients with &gt;3log Reduction of MRD Conferred a Very High Relapse and Need HSCT to Improve Outcome
Authors: Hong-Hu Zhu, Ya-Zhen Qin, Lan-Ping Xu, Qian Jiang, Xiao-Hui Zhang, Hao Jiang, Xiao-Jun Huang
Journal: Blood (2016)
Implication of the Anti-Apoptotic Protein Bcl-B (BCL2L10) in the Pathogenesis of Multiple Myeloma
Authors: Valentine Richez, Frederic Luciano, Amine Hamouda, Alexandre Puissant, Guillaume Robert, Arnaud Jacquel, Thomas Cluzeau, Kenneth C Anderson, Jean-Gabriel Fuzibet, Patrick Auberger
Journal: Blood (2015)
Plasma lipid distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. The Lipid Research Clinics Program Epidemiology Committee.
Journal: Circulation (1979)

Cross-sectional age- and sex-specific plasma lipid distributions (means, medians and selected percentiles) are given for 48,431 white participants in visit 1 of the Lipid Research Clinics (LRC) Prevalence Study. This study consisted of two visits in which 10 LRCs screened participants selected from well-defined North American target populations that included a broad range of sociodemographic subgroups. These data confirm findings from earlier studies in developed countries, showing age-related differences in plasma lipid levels. However, for overall distributions, the LRC data showed slightly lower cholesterol and markedly higher triglyceride values than those previously reported for North America. Some variation in plasma lipid values was evident among the clinic populations. The large number of participants within most subgroups permitted a variety of analytic and comparative studies. For example, data from the large pediatric population revealed a drop in plasma cholesterol levels in adolescent males and females. Males aged 20--50 years had higher cholesterol levels than females in the same age group, and higher triglyceride levels between ages 20--70 years. Numbers were also sufficient for meaningful comparisons between lipid distributions of females who were taking sex hormones and those who were not: In females taking sex hormones, cholesterol and triglyceride levels were higher for subjects younger than 45 years, but slightly lower after age 45, than lipid levels in females not taking hormones.
Abstract P3-10-08: Socio-demographic predictors for delay of treatment among a racially diverse, urban breast cancer population
Authors: NY Ko, G Patts, TA Battaglia, C Wang, GV Denis, A Hirsch, J Weinberg
Journal: Cancer Research (2017)

Abstract Background: Racial and ethnic disparity in breast cancer outcomes is a long-standing problem that continues to worsen. Recent evidence has underscored the importance of timely care, as delays in treatment can lead to decreased survival. We sought to understand predictors of delay to first treatment among a racially diverse cancer population. Methods: This is a retrospective study of breast cancer cases diagnosed between the years 2000 to 2014. Data was extracted from the cancer registry at Boston Medical Center (BMC), an urban safety net hospital. Inclusion criteria were any breast cancer diagnosis from 2000-2014, receiving first treatment at BMC, and disease stage 0-III. Cox Proportional Hazards regression analysis was performed to identify predictors of time to first treatment, defined as days from date of diagnosis to date of first treatment with surgery or neo-adjuvant chemotherapy. Covariates included age, sex, race, type of insurance, marital status, US birth, disease stage and year of diagnosis. Results: Patients were 99% female and with a mean age of 58 years (range 23-96). Among a sample of 1545 breast cancer cases, 1372 (89%) had surgery as first treatment and 173 (11%) had neoadjuvant chemotherapy. Median days to treatment was 45 days (IQR 27, 71). In the multi-variable adjusted models for both treatment groups, race, and insurance were significantly associated with delay. In the surgical group, Black race, public or no insurance, non-US born, later stage and unmarried status were associated with increased risk of delay. For example, Blacks were at higher risk for delay (HR= 1.2; 95% CI 1.37-1.04) compared to the Hispanic or White (reference) groups. Public insurance (HR = 1.19; 95%CI 1.37-1.04) and no insurance (HR = 1.43; 95%CI 1.85-1.09) was significantly associated with increased delay when compared to private insurance (reference). In patients with neoadjuvant chemotherapy as first treatment, additional significant predictors of delay were age and year of diagnosis. Conclusion: Race and insurance status were significant predictors of delay to first treatment in a population of diverse breast cancer patients seeking care at a safety net hospital. Intervention efforts need to target patients at greatest risk for treatment delays. Citation Format: Ko NY, Patts G, Battaglia TA, Wang C, Denis GV, Hirsch A, Weinberg J. Socio-demographic predictors for delay of treatment among a racially diverse, urban breast cancer population [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P3-10-08.
In-Vitro Effect of the Small Molecule Thrombopoietin (TPO) Receptor Agonist Eltrombopag in Chronic Lymphocytic Leukemia (CLL).
Authors: Thorsten Zenz, Antonio Sarno, Andrea Schnaiter, Dirk Winkler, Andreas Bühler, Matthias Volden, Connie L. Erickson-Miller, Yasser Mostafa Kamel, Hartmut Döhner, Stephan Stilgenbauer
Journal: Blood (2009)
Wilms Tumor Protein-1-Derived 9-Mer Peptide Induces CD4 T-Cell Responses in an HLA-DR Restricted Manner
Authors: Shigeo Fuji, Julia Fischer, Markus Kapp, Thomas G Bumm, Hermann Einsele, Stefan Stevanovic, Hans-Georg Rammensee, Thomas Hunig, Götz Ulrich Grigoleit
Journal: Blood (2012)
Analysis of Bleeding in Patients with Immune Thrombocytopenic Purpura (ITP): A Randomized, Double-Blind, Placebo-Controlled Trial of Eltrombopag, an Oral Platelet Growth Factor.
Authors: James B. Bussel, Gregory Cheng, Mansoor Saleh, Lidia Kovaleva, Nicole Stone, Bhabita Mayer, Julian Jenkins, Andrew Provan
Journal: Blood (2006)
AL Amyloidosis and Patient Reported Quality of Life
Authors: Rahma Warsame, Shaji Kumar, Carrie A. Thompson, Morie A. Gertz, Martha Q. Lacy, Francis Buadi, Suzanne R. Hayman, Nelson Leung, David Dingli, Yi L. Hwa, John A. Lust, Prashant Kapoor, Yi Lin, Ronald S. Go, Steven R. Zeldenrust, Robert A. Kyle, S. Vincent Rajkumar, Angela Dispenzieri
Journal: Blood (2015)
MDR Proteins Expression in AIDS-Related Non-Hodgkin’s Lymphoma.
Authors: Giselle Pinto de Faria, Luciana de Souza Barreto, Sérgio Romano, Paulo Antônio Faria, Carlos José Ferreira, Jane Dobbin, Claudete Esteves Klumb, Raquel Ciuvalschi Maia
Journal: Blood (2004)
Evolution of Bisphosphonates Related Osteonecrosis of the Jaw (BRONJ) in Patients with Multiple Myeloma (MM): A Retrospective Study
Authors: Alessandro AA Alessandro Andriani, Maria Teresa MTP Petrucci, Tommaso Caravita, Marco Montanaro, Francesco Pisani, Ugo Coppetelli, Marianna De Muro, Velia Bongarzoni, Giuseppe Avvisati, Nicoletta Villivà, Anna Levi, A. Siniscalchi, Alessandro Agrillo, Domenico Gaglioti
Journal: Blood (2008)
The epithelial to mesenchymal transition (EMT) and cancer stem cells: implication for treatment resistance in pancreatic cancer
Authors: Pingting Zhou, Bo Li, Furao Liu, Meichao Zhang, Qian Wang, Yuanhua Liu, Yuan Yao, Dong Li
Journal: Molecular Cancer (2017)

The mechanical properties of epithelial to mesenchymal transition (EMT) and a pancreatic cancer subpopulation with stem cell properties have been increasingly recognized as potent modulators of the effective of therapy. In particular, pancreatic cancer stem cells (PCSCs) are functionally important during tumor relapse and therapy resistance. In this review we have surveyed recent advances in the role of EMT and PCSCs in tumor progression, metastasis and treatment resistance, and the mechanisms of integrated with biochemical signals and the underlying pathways involved in treatment resistance of pancreatic cancer. These findings highlight the importance of confirming stem-cells markers and complex molecular signaling pathways controlling EMT and cancer stem cells in pancreatic cancer during tumor formation, progression, and response to therapy.
Immune Ontogeny and Engraftment Receptivity in the Sheep Fetus
Authors: John S. Pixley, Jessica L. Skopal-Chase, Alireza Torabi, Mihai C. Cenariu, Anupama Bhat, David S. Thain, Nicole M. Frederick, Daria M. Groza, Esmail D. Zanjani
Journal: Blood (2008)
Interplay between Immune Checkpoint Proteins and Cellular Metabolism
Authors: Sangbin Lim, Joshua B. Phillips, Luciana Madeira da Silva, Ming Zhou, Oystein Fodstad, Laurie B. Owen, Ming Tan
Journal: Cancer Research (2017)

Abstract With the recent successes in immuno-oncology, renewed interest in the role of immune checkpoint modulators, such as the B7 family proteins, has escalated. The immune checkpoint proteins play a crucial role in the regulation of cellular immunity; however, their contribution to other aspects of cancer biology remains unclear. Accumulating evidence indicate that immune checkpoint proteins can regulate metabolic energetics of the tumor, the tumor microenvironment, and the tumor-specific immune response, leading to metabolic reprogramming of both malignant cells and immune cells involved in mounting and sustaining this response. Immune cell metabolism impacts the activation status of immune cells and ultimately the immune response in cancer. Tumor cells may deplete nutrients that immune cells require for optimal generation, expansion, and function. They may also generate toxic metabolites in the microenvironment or induce conserved inhibitory pathways that impair immune function and thus inhibit antitumor responses. In this review, we will discuss how cancer cells with altered expression of immune checkpoint proteins can potently inhibit immune function through the alteration of cellular and microenvironmental metabolism, providing a new perspective on the interplay between these pathways and offering a potential therapeutic intervention strategy in the treatment of malignant disease. Cancer Res; 77(6); 1245–9. ©2017 AACR.
Performance of IFIGC/MSG/EORTC Criteria for the Diagnosis of Invasive Pulmonary Aspergillosis in the Clinical Management of Unselected Patients with Acute Leukemia.
Authors: Erika Borlenghi, Maria Adele Capucci, Chiara Cattaneo, Nicoletta Petrella, Liana Signorini, Fabio Franco, Giuseppe Rossi
Journal: Blood (2004)
Annals Story Slam - Finding the Reason
Authors: Navin Vij
Journal: Annals of Internal Medicine (2017)

Web Exclusives7 March 2017Annals On Being a Doctor Story Slam - Finding the ReasonFREENavin Vij, MDNavin Vij, MDFrom University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W17-0032 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - Finding the Reason "Finding the Reason," by Dr. Navin Vij (Duration 6:03)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: From University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.Current Author Address: Navin Vij, MD; e-mail, [email protected]edu. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 7 March 2017Volume 166, Issue 5Page: SS1 ePublished: 7 March 2017 Issue Published: 7 March 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.Loading ...